Search Results 1-20 of 46

管 析

Precision medicine = プレシジョンメディシン 3(1), 62-66, 2020-01

Ichushi Web 

Takeuchi Haruka , Takahashi-Muto Chie , Nagase Mana , Kassai Masahiro , Tanaka-Yachi Rieko , Kiyose Chikako

… In an investigation of costimulatory CD137 (<i>Tnfrsf9</i>)/CD137L inflammatory signaling, a member of the TNF super-family, sweet basil extracts inhibited <i>Tnfrsf9</i> …

Journal of Oleo Science 69(5), 487-493, 2020

J-STAGE  Ichushi Web 

兵頭 一之介 , Kohei Shitara , Taroh Satoh , Satoru Iwasa , Kensei Yamaguchi , Kei Muro , Yoshito Komatsu , Tomohiro Nishina , Taito Esaki , Jun Hasegawa , Yasuyuki Kakurai , Emi Kamiyama , Tomoko Nakata , Kota Nakamura , Hayato Sakaki , Ichinosuke HYODO

… The proportion of CD16-positive natural killer (NK) cells (CD3-CD56+CD16+) decreased 4 h after the start of DS-8895a administration, and the ratio of CD3-CD56+CD137+ to CD3-CD56+CD16+ cells increased on day 3.CONCLUSIONS:Twenty mg/kg DS-8895a infused intravenously every 2 weeks was generally safe and well tolerated in patients (n = 21) with advanced solid tumors. …

Journal for ImmunoTherapy of Cancer (7), 219, 2019-08

IR 

Söderström Leif Å. , Olofsson Peder S. , Jin Hong , Caravaca April S. , Klement Maria L. , Li Yuhuang , Gisterå Anton , Hedin Ulf , Maegdefessel Lars , Hansson Göran K.

… Co-stimulatory molecules, such as CD137, are key regulators of inflammation, and CD137 activity regulates inflammation in experimental atherosclerosis. …

Circulation Journal 81(12), 1945-1952, 2017

J-STAGE  Ichushi Web 

Tongu Miki , Harashima Nanae , Tamada Koji , Chen Lieping , Harada Mamoru

… In the current study, we examined the antitumor effects of a combination of local injection with anti-CD137 mAb and intermittent low-dose chemotherapy using CP and GEM in subcutaneously established CT26 colon carcinoma. … Although a significant antitumor effect was observed when local anti-CD137 mAb therapy (5 μg) was started early in the tumor-bearing stage (day 10), no therapeutic efficacy was observed when the mAb therapy was started at a later tumor-bearing stage (day 17). …

Cancer science 106(1), 9-17, 2015-01

IR  Ichushi Web 

OZAWA Keiya

… CARs are hybrid proteins consisting of a target-antigen-specific single-chain antibody fragment fused to intracellular T-cell activation domains (CD28 or CD137/CD3ζ receptor). …

Rinsho Ketsueki 56(10), 2180-2185, 2015

J-STAGE  Ichushi Web 

YAGITA HIDEO

… More applications of the immunostimulatory antibodies targeting costimulatory molecules, such as CD40 and CD137, and coinhibitory molecules, such as TIM-3 and VISTA, are now expected. …

Juntendo Medical Journal 60(4), 358-361, 2014

J-STAGE  Ichushi Web 

Tamura Takahiko , Kimura Kazumi , Yuda Masao , Yui Katsuyuki

… These CD8+ T cells expressed CD11c and upregulated CXCR3, while the expression of CD137, CD25, and granzyme B was reduced. …

Infection and Immunity 79(10), 3947-3956, 2011-10

IR 

CARPENITO C

Proc Natl Acad Sci USA 106, 3360-3365, 2009

Cited by (2)

OKUMURA KO

… show that induction of tumor-cell apoptosis by an agonistic monoclonal antibody to DR5, the apoptosisinducing receptor for TNF-related apoptosis-inducing ligand (TRAIL), combined with T-cell activation by agonistic monoclonal antibodies to the costimulatory molecules CD40 and CD137, potently and rapidly atimulated tumor-specific effector CD8+T cells capable of eradicating preestablished tumors.These findings in mice indicate that a rational monoclonal antibody-based therapy that both causes tumor-cell apoptosis through DR5 and activates T cells may be an …

Juntendo Medical Journal 54(2), 110-115, 2008

J-STAGE